Devyser Diagnostics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DVYSR.ST research report →
Companydevyser.com
Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up.
- CEO
- Jan Wahlstrom
- IPO
- 2021
- Employees
- 120
- HQ
- Hägersten, SE
Price Chart
Valuation
- Market Cap
- $1.58B
- P/E
- 105.49
- P/S
- 6.14
- P/B
- 4.42
- EV/EBITDA
- 27.73
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 80.28%
- Op Margin
- 10.83%
- Net Margin
- 5.82%
- ROE
- 4.31%
- ROIC
- 4.46%
Growth & Income
- Revenue
- $250.50M · 15.49%
- Net Income
- $-8,400,000 · 86.34%
- EPS
- $-0.51 · 86.40%
- Op Income
- $10.60M
- FCF YoY
- 105.42%
Performance & Tape
- 52W High
- $159.60
- 52W Low
- $74.00
- 50D MA
- $84.58
- 200D MA
- $111.70
- Beta
- 0.82
- Avg Volume
- 38.87K
Get TickerSpark's AI analysis on DVYSR.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DVYSR.ST Coverage
We haven't published any research on DVYSR.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DVYSR.ST Report →